- Dr. Daniel Muller
CV
Dr. Daniel Mueller is the Physician-in-Chief at Ontario Shores Centre for Mental Health Sciences (ontarioshores.ca), where he holds an endowed research chair for Personalized Medicine. At Ontario Shores, he is the site PI for Canada’s largest depression research network (canbind.ca), overseeing clinical trials to identfiy biomarkers associated with response and side effects to antidepressant and antipsychotic medications.
He is Professor at the Department of Psychiatry at the University of Toronto and Director of the Fellowship Program.
Dr. Mueller developed the first pharmacogenetic testing service for psychiatric patients in Canada at the Centre for Addiction and Mental Health (CAMH) in Toronto.
He has published over 300 peer-reviewed articles and received international recognitions for his innovative research and implementation strategies on pharmacogenetics.
Dr. Mueller is the president of the Canadian College of Neuropsychopharmacology (ccnp.ca).
ABSTRACT
The implementation of pharmacogenetics into practice is supported by dosing guidelines developed by expert groups such as the Clinical Pharmacogenetics Implementation Consortium, and the Dutch Pharmacogenetics Working Group. Pharmacogenetic-based dosing guidelines endorsed by these expert groups cover most antidepressants (i.e., selective serotonin reuptake inhibitors, tricyclics), several antipsychotics (i.e. aripiprazole, quetiapine, risperidone, zuclopenthixol), anticonvulsants (i.e., carbamazepine, oxcarbazepine, phenytoin), anxiolytics (i.e., clobazam, diazepam), and ADHD medications (i.e., amphetamine, atomoxetine). The aims of the presentation consists in: (1) reviewing current evidence-based guidelines, (2) reviewing some real-world implementation strategies for pharmacogenetic testing in clinical practice and (3) highlighting promising research in psychiatric pharmacogenetics such using polygenic risk scoring or testing for ApoE4 gene variants to guide mdeications for Alzheimer’s.